Lo et al. conducted a systematic review and meta-analysis to assess the efficacy of SGLT2 inhibitors in cardiovascular and renal outcomes, especially with eGFR <60 ml/min/1.73 m2 in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.